Fate Therapeutics, Inc.

NASDAQ:FATE

Biotechnology

Healthcare
$1.05 -0.00%

-$0.00 today

Market cap
$122.39M
Beta
2.52
P/E (TTM)
-1.8
EPS (TTM)
-$1.08
52W Low $0.91High $2.88

Volume 1.87M

Average 2.92M

FATE Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Fate Therapeutics, Inc.NASDAQ: FATE

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to -124.6%

Gross margin was -124.6% in Q1 FY2026, up 1563.9 pp from a year earlier. On a trailing-twelve-month basis it was -415.8%, up 126.5 pp year over year. Over 3 fiscal years it narrowed by 179.8 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-124.6%-224.6 pp QoQ
Last fiscal yearDec 2025
-94.1%+675.5 pp YoY
LTMMar 2026
-415.8%+126.5 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1563.9 pp——
1 year+675.5 pp——
3 years-179.8 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
-94.1%
Year-over-year change
+675.5pp

Gross Margin vs competitors

How FATE compares with its peers on the latest reported figures

  • FATE's LTM Mar 2026 gross margin of -415.8% is the lowest of the 4 companies compared; the peer median is 97.7%.
  • Its year-over-year change of +126.5 pp is the highest of 4, against a peer median of -2.3 pp.
  • Over three fiscal years its change of -179.8 pp compares with a peer median of -23.0 pp.
FATE Competitors Peer median
Gross Margin for FATE and competitors
Company Period LTM level YoY 3-year change
INOInovio Pharmaceuticals, Inc.FY2025100.0% +0.0 pp+0.0 pp
PRLDPrelude Therapeutics IncorporatedLTM Mar 202697.7% -2.3 pp—
ALECAlector, Inc.LTM Mar 2026-61.2% -68.0 pp-45.9 pp
FATEFate Therapeutics, Inc.LTM Mar 2026-415.8% +126.5 pp-179.8 pp
VORVor Biopharma Inc.FY2025— ——
PEPGPepGen Inc.FY2025— ——
MOLNMolecular Partners AGFY2025— ——
NKTXNkarta, Inc.FY2025— ——
CRBPCorbus Pharmaceuticals Holdings, Inc.FY2025— ——
ABOSAcumen Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding FATE) 97.7%-2.3 pp-23.0 pp

Competitors are the stored peer set for FATE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.85M96.3M63.53M13.63M6.65M
Cost of Revenue5.85M13.76M157.19M118.53M12.9M
Gross Profit50M82.54M(93.65M)(104.9M)(6.26M)
Gross Margin89.5%85.7%-147.4%-769.6%-94.1%
Research & Development215.52M320.45M172.6M135M107.83M
Selling, General & Admin57.32M84.23M96.86M90.64M46.52M
Operating Expenses266.99M390.93M96.86M105.38M141.45M
Depreciation & Amortization5.85M13.76M18.28M18.96M9.3M
EBITDA(206.3M)(267.96M)(142.65M)(176.58M)(127.02M)
EBITDA Margin-369.4%-278.3%-224.5%-1295.4%-1911.2%
Operating Income(216.99M)(308.39M)(190.51M)(210.28M)(147.7M)
Operating Margin-388.6%-320.2%-299.9%-1542.6%-2222.4%
Interest Income1.31M5.84M17.19M17.29M11.05M
Interest Expense00000
Other Income / Expenses4.84M26.67M29.58M24.01M11.39M
Income Before Tax(212.15M)(281.72M)(160.93M)(186.26M)(136.32M)
Pre-Tax Margin-379.9%-292.5%-253.3%-1366.5%-2051.1%
Income Tax Expense00000
Net Income(212.15M)(281.72M)(160.93M)(186.26M)(136.32M)
Net Margin-379.9%-292.5%-253.3%-1366.5%-2051.1%
EPS (Basic)(2.24)(2.91)(1.64)(1.64)(1.15)
EPS (Diluted)(2.24)(2.91)(1.64)(1.64)(1.15)
Weighted Avg Shares94.75M96.83M98.41M113.69M118.79M
Weighted Avg Shares (Diluted)94.75M96.83M98.41M113.69M118.79M

Fate Therapeutics, Inc.

NASDAQ:FATE

Intrinsic Alpha fair value

Locked

Current Price

$1.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.